Replies to post #52189 on $heff's $tation of $tocks & $olid DD

[StimulatedCell]

DNDN--holding 95% of my original shares---not something to brag about, from as far back as 2001.

New CEO, new focus on lowering COG, expected greater usage by large urology groups as they get comfortable with reimbursement and administration of drug.

New 2-3 quarters are KEY to regain revenue growth and Wall Street's confidence. I am holding and buying under $11.